Alzheimer's community awaits FDA vote on Biogen's Aducanumab

CNBC’s Meg Tirrell joins ‘The News with Shepard Smith’ to discuss Biogen's Alzheimer’s drug Aducanumab as patients await its FDA approval. The FDA will issue the decision by June 7.